RAF1 and hepatocellular carcinoma: Sorafenib, a multiple-target tyrosine kinase inhibitor (TKI), can inhibit the proliferation of HCC cells by inhibiting the kinase activity of Raf-1, B-Raf, and Ras/Raf/MEK/ERK signaling pathways.